Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/17/17
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 10/19/20
End: 09/30/21
Due: 09/30/22
Phase: N/A
Priority: Normal
Start: 06/21/22
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 10/26/23
End: 07/31/29
Due: 07/31/30
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase I Study of AL8326 in Advanced Solid Tumor | NCT04890587 | Advenchen Laboratories Nanjing Ltd. | user2@example.com | None | 2017-08-17 | 2023-12-31 | 2024-12-31 | - | - | 2025-07-14 |
| A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | NCT04890795 | Advenchen Laboratories Nanjing Ltd. | user2@example.com | None | 2020-10-19 | 2021-09-30 | 2022-09-30 | - | - | 2025-07-14 |
| A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects | NCT05486598 | Advenchen Laboratories Nanjing Ltd. | user2@example.com | None | 2022-06-21 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |
| A Phase IIII Study of AL8326 in Small Cell Lung Cancer | NCT06247605 | Advenchen Laboratories Nanjing Ltd. | user2@example.com | None | 2023-10-26 | 2029-07-31 | 2030-07-31 | - | - | 2025-07-14 |